High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa H, et al. Hypertens Res. 2009;32:

Patients’ baseline characteristics Late-breaking clinical trial ACC 60th Annual Scientific session, April 5,2011, New Orleans.

Results

Summary The OSCAR study is the first large clinical trial to investigate the effect of high-dose ARB versus ARB plus CCB in high-risk elderly hypertensive patientsThe OSCAR study is the first large clinical trial to investigate the effect of high-dose ARB versus ARB plus CCB in high-risk elderly hypertensive patients Blood pressure was significantly lower in the ARB plus CCB group than in the high-dose ARB group.Blood pressure was significantly lower in the ARB plus CCB group than in the high-dose ARB group. There were no significant differences in primary end point rate, nor any differences in reducing CV events/non CV death between the groupsThere were no significant differences in primary end point rate, nor any differences in reducing CV events/non CV death between the groups In subgroup of patients with CV disease, primary end point rate was significantly higher in the high-dose ARB group than ARB plus CCB group (P=0.0261).In subgroup of patients with CV disease, primary end point rate was significantly higher in the high-dose ARB group than ARB plus CCB group (P=0.0261). Late-breaking clinical trial ACC 60th Annual Scientific session, April 5,2011, New Orleans.